12:00 AM
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Arbaclofen placarbil: Phase III start

After discussions with FDA, XenoPort said it plans to start a placebo-controlled Phase III trial and a long-term, open-label safety study of arbaclofen placarbil in 1H11. XenoPort said...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >